Remicade (infliximab): Side effects, dosage, cost, and more
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials | Arthritis Research & Therapy | Full
PDF) Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Mohammed M. Kamil Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics Immunogenicity of the biosimilar CT-P13
Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study | Annals of the
FRI0128 A NOVEL FORMULATION OF CT-P13 (INFLIXIMAB BIOSIMILAR) FOR SUBCUTANEOUS ADMINISTRATION: 1-YEAR RESULTS FROM A PART 1 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS | Annals of
Top developments in biosimilars during 2019 - GaBI Journal
New study trials use of CT-P13 to accelerate COVID-19 recovery - Pf Media
Biosimilar infliximab introduction into the gastroenterology care pathway in a large acute Irish teaching hospital: a story behind the evidence - GaBI Journal
CT-P13 100mg_Infusion Card(IE)_ver5
PDF) Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial
PDF) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the inflix
PDF) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease
Therapeutic Drug Monitoring of Biosimilars in Autoimmune Diseases - Stratech
CT-P13 switch pathway. IFX infliximab | Download Scientific Diagram
Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration | Business Wire
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study - The Lancet
Subcutaneous Infliximab In The US Defining CT-P13 SC's Competitive Edge
Biosimilar Remicade® – the cost-saving benefits - Hospital Pharmacy EuropeHospital Pharmacy Europe
Subcutaneous Infliximab In The US Defining CT-P13 SC's Competitive Edge
Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar | Scientific Reports
Medicina | Free Full-Text | The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease - ScienceDirect
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials | Arthritis Research & Therapy | Full
